Ticker
AERI

Price
15.10
Stock movement down
-0.08 (-0.53%)
Company name
Aerie Pharmace
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Markedsverdi
734.21M
Ent verdi
1.20B
Pris/omsetning
3.65
Pris/bok
-
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
2.58%
3 års avkastning
-12.92%
5 års avkastning
-21.90%
10 års avkastning
-
Sist oppdatert: 2022-08-25

UTBYTTE

AERI betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning3.65
Pris til bok-
EV i forhold til salg5.97

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall48.62M
EPS (TTM)-1.44
FCF per aksje (TTM)-0.24

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)201.00M
Bruttofortjeneste (TTM)174.07M
Driftsinntekter (TTM)-45.78M
Netto inntekt (TTM)-68.74M
EPS (TTM)-1.44
EPS (1 år fremover)-1.26

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)86.60%
Driftsmargin (TTM)-22.78%
Fortjenestemargin (TTM)-34.20%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter56.44M
Netto fordringer63.62M
Samlede omløpsmidler316.97M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler395.55M
Leverandørgjeld7.88M
Kortsiktig/nåværende langsiktig gjeld337.18M
Sum kortsiktig gjeld115.29M
Sum gjeld521.26M
Aksjonærenes egenkapital-125.71M
Netto varige driftsmidler-125.71M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-7.19M
Kapitalutgifter (TTM)4.12M
Fri kontantstrøm (TTM)-11.30M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-
Avkastning på eiendeler-17.38%
Avkastning på investert kapital56.69%
Kontantavkastning på investert kapital9.32%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning15.15
Daglig høy15.16
Daglig lav15.09
Daglig volum3.48M
Tidenes høyeste73.90
1 år analytikerestimat18.67
Beta0.40
EPS (TTM)-1.44
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon2 Nov 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
AERIS&P500
Nåværende prisfall fra toppnotering-79.57%-12.18%
Høyeste prisfall-93.30%-56.47%
Dato for høyeste fall1 Jun 20229 Mar 2009
Gj.snittlig fall fra topp-44.91%-11.38%
Gj.snittlig tid til ny topp26 days12 days
Maks tid til ny topp1034 days1805 days
SELSKAPSOPPLYSNINGER
AERI (Aerie Pharmace) company logo
Markedsverdi
734.21M
Markedsverdi kategori
Small-cap
Beskrivelse
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Ansatte
376
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Vicente J. Anido
Land
USA
By
Durham
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best.
20. september 2022
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
20. september 2022
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.
13. september 2022
DURHAM, N.C., September 13, 2022--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapi...
13. september 2022
Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.
12. september 2022
Here is how Aerie Pharmaceuticals (AERI) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
12. september 2022
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
8. september 2022
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
7. september 2022
In this article, we will discuss how hedge funds were right about these 10 small-cap stocks. To skip our detailed analysis of well-performing industries in 2022, go directly and see Hedge Funds Were R...
2. september 2022
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
1. september 2022
Neste side